Fox Run Management L.L.C. Invests $588,000 in Edwards Lifesciences Corp (EW) Stock

Fox Run Management L.L.C. bought a new stake in Edwards Lifesciences Corp (NYSE:EW) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,039 shares of the medical research company’s stock, valued at approximately $588,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Wendell David Associates Inc. raised its stake in Edwards Lifesciences by 4.0% in the 2nd quarter. Wendell David Associates Inc. now owns 9,548 shares of the medical research company’s stock valued at $1,390,000 after purchasing an additional 363 shares during the last quarter. IHT Wealth Management LLC grew its holdings in Edwards Lifesciences by 84.6% in the 1st quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock valued at $126,000 after buying an additional 427 shares during the period. Gulf International Bank UK Ltd grew its holdings in Edwards Lifesciences by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 66,330 shares of the medical research company’s stock valued at $9,254,000 after buying an additional 450 shares during the period. Daiwa Securities Group Inc. grew its holdings in Edwards Lifesciences by 9.1% in the 1st quarter. Daiwa Securities Group Inc. now owns 6,891 shares of the medical research company’s stock valued at $961,000 after buying an additional 572 shares during the period. Finally, WealthPLAN Partners LLC grew its holdings in Edwards Lifesciences by 22.2% in the 1st quarter. WealthPLAN Partners LLC now owns 3,225 shares of the medical research company’s stock valued at $450,000 after buying an additional 585 shares during the period. 81.27% of the stock is owned by hedge funds and other institutional investors.

Get Edwards Lifesciences alerts:

Several analysts have commented on EW shares. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Saturday, July 14th. ValuEngine upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Tuesday, June 12th. SunTrust Banks restated a “buy” rating and issued a $180.00 price target on shares of Edwards Lifesciences in a report on Tuesday, April 10th. Sanford C. Bernstein started coverage on Edwards Lifesciences in a report on Wednesday, June 27th. They issued a “market perform” rating and a $165.00 price target for the company. Finally, Northland Securities cut Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 25th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $152.65.

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 9th. The stock was sold at an average price of $134.73, for a total value of $3,368,250.00. Following the completion of the transaction, the chief financial officer now owns 35,968 shares in the company, valued at approximately $4,845,968.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction that occurred on Monday, April 30th. The stock was sold at an average price of $128.46, for a total value of $4,213,488.00. Following the completion of the transaction, the chief executive officer now owns 74,131 shares of the company’s stock, valued at approximately $9,522,868.26. The disclosure for this sale can be found here. Insiders have sold a total of 230,249 shares of company stock valued at $31,802,645 in the last quarter. Company insiders own 1.84% of the company’s stock.

Shares of NYSE:EW opened at $152.62 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.07 and a quick ratio of 1.63. Edwards Lifesciences Corp has a 1 year low of $100.20 and a 1 year high of $155.22. The stock has a market cap of $31.68 billion, a PE ratio of 36.83, a PEG ratio of 2.20 and a beta of 0.64.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, April 24th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.11. Edwards Lifesciences had a return on equity of 28.60% and a net margin of 17.36%. The business had revenue of $938.00 million during the quarter, compared to analysts’ expectations of $936.69 million. During the same quarter in the previous year, the business earned $0.94 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. sell-side analysts forecast that Edwards Lifesciences Corp will post 4.63 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Understanding Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Here's What Every Investor Needs to Know About the Next Six Months

William Patalon III

A decade has passed since I first met�our Chief Investment Strategist Keith Fitz-Gerald�– and from that first day, the big-payoff investing ideas have just kept rolling in.

So I invited Keith to share his best ideas – and best strategies – for the last six months of 2018. It's going to be a challenging stretch – with unforeseen "wild cards" roiling already-turbulent waters.

He shared some incredible stock recommendations. He also offered one of the simplest – but most profound – bits of advice about surviving and thriving in the second half of this year. In fact, I'll share it before we get started:

"Right, now, BP, with all the wild cards, with all the uncertainty, with all the worries folks have – I still don't see this as a time to cut and run," said Keith.

He went on, "To me, the stock market at this time is about playing to strengths – and�not�bowing down to weaknesses. It's about being tactically opportunistic – and�not�'hunkering down.' I say all this for one very good reason: Threats and opportunities are just different sides of the same coin. It's all about how you look at things."

That's a "winner's way" of looking at things, as evidenced by the long list of double- and triple-digit winning stocks he's researched and recommended for his Money Map Report and High Velocity Profits subscribers in the first half of 2018.

Here's how he plans to build on that success in the months ahead…

Join the conversation. Click here to jump to comments…

William Patalon III

About the Author

Browse William's articles | View William's research services

Before he moved into the investment-research business in 2005, William (Bill) Patalon III spent 22 years as an award-winning financial reporter, columnist, and editor. Today he is the Executive Editor and Senior Research Analyst for Money Morning. With his latest project, Private Briefing, Bill takes you "behind the scenes" of his established investment news website for a closer look at the action. Members get all the expert analysis and exclusive scoops he can't publish... and some of the most valuable picks that turn up in Bill's closed-door sessions with editors and experts.

… Read full bio

Ideal Power (IPWR) Downgraded by Zacks Investment Research

Ideal Power (NASDAQ:IPWR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Ideal Power, Inc. is engaged in development of a novel, patented power conversion technology called Power Packet Switching Architecture(TM). The company also provides photovoltaic inverters and battery converters for grid storage and electrified vehicle fast-charging infrastructure. In addition, it offers hybrid power conversion systems and power switches. Ideal Power, Inc. is based in Spicewood, Texas. “

Get Ideal Power alerts:

A number of other equities research analysts have also weighed in on the stock. ValuEngine upgraded shares of Ideal Power from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. B. Riley restated a “hold” rating on shares of Ideal Power in a research note on Monday, May 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $2.19.

Shares of IPWR opened at $0.96 on Wednesday. The firm has a market cap of $14.42 million, a price-to-earnings ratio of -1.23 and a beta of 1.11. Ideal Power has a 1-year low of $0.92 and a 1-year high of $3.29.

Ideal Power (NASDAQ:IPWR) last announced its earnings results on Thursday, May 10th. The industrial products company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). The business had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.32 million. Ideal Power had a negative net margin of 833.16% and a negative return on equity of 75.12%. equities research analysts predict that Ideal Power will post -0.56 earnings per share for the current year.

Ideal Power Company Profile

Ideal Power Inc develops power conversion solutions with a focus on solar and storage, microgrid, and stand-alone energy storage applications. It operates through two Divisions, Power Conversion Systems and B-TRAN. The Power Conversion Systems Division focuses on its Power Packet Switching Architecture technology.

Featured Article: What does RSI mean?

Get a free copy of the Zacks research report on Ideal Power (IPWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Mahindra CIE Q1 PAT seen up 45.5% YoY to Rs. 125.6 cr: ICICI Direct

ICICI Direct has come out with its first quarter (April-June�� 18) earnings estimates for the Automobiles sector. The brokerage house expects Mahindra CIE to report net profit at Rs. 125.6 crore up 45.5% year-on-year (up 7.9% quarter-on-quarter).

Net Sales are expected to increase by 17.4 percent Y-o-Y (down 1.5 percent Q-o-Q) to Rs. 1,772.6 crore, according to ICICI Direct.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 23.9 percent Y-o-Y (up 4.4 percent Q-o-Q) to Rs. 255 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More First Published on Jul 18, 2018 12:46 pm

ResTORbio Bounces Back: Is the Biotech Stock a Buy?

ResTORbio, Inc. (NASDAQ:TORC) has had a fairly underwhelming start to public trading. The company completed its IPO earlier this year with an offering price of $15/share. TORC stock came out of the gate successfully, opening trading around the $18/share level. After hitting $21, however, things went south for resTORbio.

By April, TORC stock had fallen to below $8, losing half of its IPO value. Since then, resTORbio has seen a series of ups and downs. The stock hit $12 in May, fell back to the $8s, hit $12 again in June, and recently found itself back at $8. However, on Wednesday, resTORbio put in a sharp bounce, with shares rallying more than 10% off that support level. What reawakened TORC stock, and will it lead to further gains going forward?

What Is resTORbio Trying To Achieve?

As you might guess from the company’s capitalization of “TOR” and its ticker symbol, TOR is an important concept for the company. In particular, it stands for mTOR, a gene that is closely tied to aging in both mammals in general and humans specifically.

Needless to say, this genetic pathway could be a huge deal for medical research. The company’s name hints at restoration. A drug company that could tinker with the genes tied to aging could potentially make a fortune. mTOR drug inhibitors have been shown to extend the lifespans of mice. A similar finding, if it were to occur in humans, would be ground-breaking. mTOR also appears to be linked to cancers, and perhaps Alzheimer’s, autism, and other brain dysfunctions.

For now, however, resTORbio is starting off with more modest ambitions. The company’s main drug candidate, RTB101, focuses on lowering the number of respiratory tract infections that older people experience. RTIs are a major problem for people above the age of 65, leading to frequent hospitalizations.

In the company’s prospectus, they show Phase IIa data demonstrating that their drug appears to lower RTI occurrences around 40% or so compared to the placebo. If that result holds through more rigorous testing, it would be a major development, as RTIs are a large problem and thus the potential market could be vast.

What Happened This Week

TORC stock popped on Wednesday following a company press release highlighting more clinical data for their main drug. Their press release started off with the following news:

“resTORbio today announced newly published data from a Phase 2a clinical trial demonstrating that target of rapamycin complex 1 (TORC1) inhibitor treatment improved immune function and decreased incidence of all infections, including respiratory tract infections (RTIs), in people aged 65 years and older. RTIs in particular are a significant health risk for the elderly with life-threatening consequences and few treatment options. Data were published in the July 11, 2018 online edition of the journal Science Translational Medicine.”

The press release goes on to detail said finds from the study. It’s worth noting, however, that this data is not all that dissimilar to data that the company reported in its prospectus, though it does reaffirm those numbers.

This wasn’t the big catalyst that investors were waiting for, as we can see with the relatively muted response in the price of TORC stock. Instead, investors are looking forward to data readouts from the company’s Phase IIb trial which is expected in the first part of 2019. The company is running an additional trial with older and more at-risk folks, such as those with diabetes. If the drug shows similar efficacy in this higher stakes setting, it’d do a lot to increase the drug’s commercial prospects.

How Long Is Their Runway?

One of the pivotal questions for a clinical-stage biotech company is how long their cash will last. Since a biotech company with no approved drugs has minimal revenues, its cash position is of utmost importance.

Compare Brokers

In the case of resTORbio, the company had $135.7 million in cash at the end of March. That seems like a meaty cash position, given that the company only had a net loss of $41 million last year. However, the company is ramping up its spending post-IPO to power through its clinical trials. As a result, the company states that it has enough cash to last at least 12 months. But a capital raise later in 2019 wouldn’t be surprising.

For TORC stock, a key question will be when the company seeks to raise more money. The pivotal data readout is supposed to come in early 2019 with the Phase IIb trial results. If the drug shows strong efficacy, TORC stock should surge, making a capital raise significantly less dilutive. On the other hand, weak data would likely tank the stock. That’s especially true since resTORbio’s doesn’t have that much else in the clinical pipeline.

TORC Stock Verdict

As is often the case with clinical-stage biotech companies, this is a high-risk, high-reward venture. Even if the clinical data from the Phase IIb trial is good, resTORbio would still have to make it through Phase III, where many previously promising drugs end up failing to demonstrate statistical efficacy. It will still be a couple of years before resTORbio could potentially have an approved drug, meaning that the company will be reliant on the capital markets for funding. These ingredients make for a volatile stock price in the interim.

Additionally, it’s worth considering that resTORbio got access to this drug platform due to Novartis AG (NYSE:NVS) unloading it for a modest financial consideration and some equity in the company. Novartis executed a similar move with the UK biotech firm Mereo several years ago, and that one hasn’t been a winner as of yet. As always, it’s worth asking why Novartis would let this drug candidate go if it felt highly of its prospects.

Long story short, as it goes with clinical-stage biotech companies, there is loads of upside potential here. But a bad trial result could send shares down 50% or more. If you like the platform, the stock looks interesting here bouncing off technical support. Keep position sizes appropriate, however, considering the significant downside risk.

At the time of this writing, the author had no positions in the aforementioned securities.

Legendary Investor Louis Navellier’s #1 Stock to Buy NOW

Louis Navellier — the investor the New York Times called an “icon” — just helped investors make 487% in the booming Chinese stock market … 408% in the medical device sector … 150% in Netflix … all in less than 2 years! Now, Louis is urging investors to get in on what may be the opportunity of a lifetime. By using a unique investment strategy called “The Master Key,” you could make hundreds of percent returns over the next few years. Click here to learn about the #1 stock recommendation from one of America

Why Glu Mobile Inc. Stock Gained 13.7% in June

What happened

Shares of Glu Moble�(NASDAQ:GLUU)�climbed 13.7% in June, according to data from�S&P Global Market Intelligence�.�The mobile-gaming company's share price has climbed roughly 80% year to date on indications that its turnaround effort is proceeding successfully.�

GLUU data by YCharts

Glu is aiming to improve player engagement and spending on its legacy titles such as�Kim Kardashian Hollywood, Covet Fashion, and Design Home while also launching new franchises -- and it's seen encouraging early results for recent release�MLB Tap Sports Baseball 2018. The stock also gained ground following favorable ratings coverage from Piper Jaffray.

Image source: Getty Images.

So what

Glu posted better-than-expected earnings results at the beginning of May, helping to push its share price roughly 29% higher in the month. The successful debut of MLB Tap Sports Baseball 2018 also added to its stock gains, and some of the momentum from those catalysts carried on through June.

On June 15, Piper Jaffray analyst Michael Olson initiated ratings coverage on the stock, issuing an "overweight" rating and setting a $7.50 price target -- representing roughly 20% upside at the time of the note's publication and the stock's price as of this writing.�Glu is a relatively small company with a market cap of roughly $850 million, so it's not unusual to see its valuation post significant gains following positive coverage from a highly regarded ratings firm.

Now what

Glu's valuation has seen some big swings since the company went public in 2007.

GLUU data by YCharts

Much of the volatility has been tied to shifts in the company's section of the gaming industry -- with the rise and fall of Facebook-based browser games and celebrity-focused titles being among the most notable changes to impact performance.

Glu has recently had success with its pivot away from celebrity-focused games, with 69% of its bookings in the March-ended quarter coming from original intellectual properties. However, there are still reasons to be cautious about the company's long-term prospects. The mobile-games space is highly competitive, and Glu will have to contend with more resource-rich competitors such as�Activision Blizzard, Electronic Arts, and Take-Two Interactive, as well as a wide range of smaller independent studios.

Despite favorable trends shaping the broader gaming industry, there's limited visibility on how the company's efforts to introduce new properties will fare -- so those considering buying Glu Mobile should proceed with the understanding that it's not a low-risk investment.

Funko Inc (FNKO) Expected to Announce Quarterly Sales of $122.76 Million

Equities research analysts expect Funko Inc (NASDAQ:FNKO) to post sales of $122.76 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Funko’s earnings, with the lowest sales estimate coming in at $117.10 million and the highest estimate coming in at $126.89 million. The business is scheduled to issue its next earnings report on Thursday, August 9th.

According to Zacks, analysts expect that Funko will report full-year sales of $614.80 million for the current financial year, with estimates ranging from $610.30 million to $626.61 million. For the next fiscal year, analysts forecast that the business will post sales of $694.25 million per share, with estimates ranging from $680.20 million to $712.36 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Funko.

Get Funko alerts:

Funko (NASDAQ:FNKO) last posted its quarterly earnings results on Thursday, May 10th. The company reported $0.04 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.05. The firm had revenue of $137.20 million during the quarter, compared to analyst estimates of $122.64 million. The company’s revenue for the quarter was up 38.4% compared to the same quarter last year.

Separately, Zacks Investment Research upgraded Funko from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Wednesday, July 4th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Funko presently has an average rating of “Buy” and an average target price of $12.67.

A number of hedge funds and other institutional investors have recently modified their holdings of FNKO. California Public Employees Retirement System bought a new position in Funko in the fourth quarter worth about $2,496,000. BlackRock Inc. bought a new position in Funko in the fourth quarter worth about $3,542,000. Allianz Asset Management GmbH bought a new position in Funko in the fourth quarter worth about $831,000. Geode Capital Management LLC bought a new position in Funko in the fourth quarter worth about $137,000. Finally, Deutsche Bank AG bought a new position in Funko in the fourth quarter worth about $157,000. 9.84% of the stock is currently owned by hedge funds and other institutional investors.

Funko opened at $13.82 on Tuesday, MarketBeat.com reports. The stock has a market capitalization of $718.40 million and a P/E ratio of 46.07. Funko has a one year low of $5.81 and a one year high of $15.16. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.63 and a quick ratio of 1.01.

Funko Company Profile

Funko, Inc, a pop culture consumer products company, designs, sources, and distributes licensed pop culture products in the United States, China, Vietnam, and the United Kingdom. The company offers vinyl, bobble head, blind-packed miniature, and action figures; and plush products, accessories, apparels, and homewares, as well as bags, purses, and wallets.

Get a free copy of the Zacks research report on Funko (FNKO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Safest Stocks To Own For 2019

tags:BCOV,CGI,DCT,CRT,

On the lookout for safe dividends? (Who isn’t, right?)

These days, you generally have three options: large-cap stocks with long dividend histories, municipal bonds and US Treasuries.

Treasuries are considered the safest of that group, and large-cap stocks the riskiest, but they’re still much safer than plenty of other investments, such as small caps and junk bonds.

I’ll show you two low-risk investments that are great buys now in a moment. But first, I want to tell you why recent events have called the safety of some of the options I just named into question.

Let’s start by looking at the following chart:

“Safe” Assets Turn Volatile

First, note how the iShares S&P National AMT-Free Municipal Bond Fund (MUB), a good proxy for municipal bonds as a whole, is the least volatile of the three funds shown above. But right now, it faces a steep downturn relative to its earlier stability.

Best Safest Stocks To Own For 2019: Brightcove Inc.(BCOV)

Advisors' Opinion:

• [By Stephan Byrd]

  These are some of the news headlines that may have effected Accern’s scoring:

  Get Brightcove alerts: Critical Analysis: Brightcove (BCOV) vs. Smartsheet (SMAR) (americanbankingnews.com) Brightcove (BCOV) PT Raised to $13.00 at Stifel Nicolaus (americanbankingnews.com) Brightcove Pushes the Envelope with Video Experiences that Increase Customer ROI (finance.yahoo.com) Brightcove Launches OTT Flow X, Powered by Accedo (finance.yahoo.com)

  A number of research analysts have recently issued reports on BCOV shares. Zacks Investment Research cut shares of Brightcove from a “buy” rating to a “hold” rating in a research note on Wednesday, April 25th. Dougherty & Co lifted their target price on shares of Brightcove from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 17th. BidaskClub upgraded shares of Brightcove from a “hold” rating to a “buy” rating in a research report on Saturday, April 28th. TheStreet upgraded shares of Brightcove from a “d+” rating to a “c-” rating in a research report on Monday, May 7th. Finally, Stifel Nicolaus boosted their price objective on shares of Brightcove from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, May 22nd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $9.85.

Best Safest Stocks To Own For 2019: Celadon Group, Inc.(CGI)

Advisors' Opinion:

• [By Stephan Byrd]

  Russell Investments Group Ltd. boosted its position in shares of Celadon Group, Inc. (NYSE:CGI) by 26.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,347,089 shares of the transportation company’s stock after purchasing an additional 283,476 shares during the quarter. Russell Investments Group Ltd. owned about 4.76% of Celadon Group worth $4,983,000 as of its most recent filing with the Securities and Exchange Commission.

• [By Ethan Ryder]

  Scopus Asset Management L.P. reduced its holdings in shares of Celadon Group, Inc. (NYSE:CGI) by 57.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 900,000 shares of the transportation company’s stock after selling 1,218,285 shares during the quarter. Scopus Asset Management L.P. owned approximately 3.18% of Celadon Group worth $3,330,000 as of its most recent filing with the SEC.

Best Safest Stocks To Own For 2019: DCT Industrial Trust Inc(DCT)

Advisors' Opinion:

• [By Joseph Griffin]

  Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of DCT Industrial Trust Inc (NYSE:DCT) by 7.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,570 shares of the real estate investment trust’s stock after acquiring an additional 1,044 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in DCT Industrial Trust were worth $821,000 as of its most recent filing with the Securities and Exchange Commission.

• [By ]

  For an "Executive Decision" segment, Cramer spoke with Hamid Moghadam, chairman and CEO of the logistics REIT, Prologis Inc.  (PLD) , which recently announced the acquisition of DCT Industrial Trust (DCT) .

• [By Stephan Byrd]

  Teza Capital Management LLC bought a new stake in DCT Industrial Trust Inc (NYSE:DCT) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,379 shares of the real estate investment trust’s stock, valued at approximately $359,000.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on DCT Industrial Trust (DCT)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Daiwa Securities Group Inc. lifted its holdings in DCT Industrial Trust Inc (NYSE:DCT) by 25.5% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 19,700 shares of the real estate investment trust’s stock after purchasing an additional 4,000 shares during the period. Daiwa Securities Group Inc.’s holdings in DCT Industrial Trust were worth $1,110,000 at the end of the most recent quarter.

Best Safest Stocks To Own For 2019: Cross Timbers Royalty Trust(CRT)

Advisors' Opinion:

• [By Ethan Ryder]

  News stories about Cross Timbers Royalty Trust (NYSE:CRT) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cross Timbers Royalty Trust earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the oil and gas company an impact score of 47.0297657024049 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Hot Dividend Stocks To Invest In 2019

tags:PTIE,ESLT,AUPH,

LSB Industries (NYSE: LXU) and Minerals Technologies (NYSE:MTX) are both multi-sector conglomerates companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Dividends

Get LSB Industries alerts:

Minerals Technologies pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. LSB Industries does not pay a dividend. Minerals Technologies pays out 4.4% of its earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for LSB Industries and Minerals Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LSB Industries 0 0 0 0 N/A Minerals Technologies 0 1 0 0 2.00

Earnings & Valuation

Hot Dividend Stocks To Invest In 2019: Pain Therapeutics(PTIE)

Advisors' Opinion:

• [By Chris Lange]

  Pain Therapeutics Inc. (NASDAQ: PTIE) shares were destroyed on Wednesday after a vote from the U.S. Food and Drug Administration (FDA) was announced. As we have said before, the FDA has the potential to make or break biopharmaceutical companies. In this case, Pain Therapeutics has been broken.

• [By Lisa Levin] Gainers Blink Charging Co. (NASDAQ: BLNK) shares climbed 31.68 percent to close at $7.19 on Wednesday. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million. Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares gained 24.15 percent to close at $3.29. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share. 21Vianet Group, Inc. (NASDAQ: VNET) shares surged 24 percent to close at $6.82. Check-Cap Ltd. (NASDAQ: CHEK) gained 20.25 percent to close at $4.87. HUYA Inc. (NYSE: HUYA) shares surged 18.42 percent to close at $22.50 Abaxis, Inc. (NASDAQ: ABAX) rose 16.15 percent to close at $83.34. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash. Pain Therapeutics, Inc. (NASDAQ: PTIE) shares jumped 16.07 percent to close at $10.62. Bilibili Inc. (NASDAQ: BILI) rose 16.04 percent to close at $14.11. Gemphire Therapeutics Inc. (NASDAQ: GEMP) gained 14.88 percent to close at $6.33. Phoenix New Media Limited (NYSE: FENG) rose 13.96 percent to close at $5.55. Daqo New Energy Corp. (NYSE: DQ) jumped 13.88 percent to close at $67.27 on Wednesday. Sea Limited (NYSE: SE) jumped 12.59 percent to close at $11.98 after reporting Q1 results. Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 12.01 percent to close at $5.13. Ascena Retail Group, Inc. (NASDAQ: ASNA) gained 11.93 percent to close at $3.19. Boot Barn Holdings, Inc. (NYSE: BOOT) climbed 11.66 percent to close at $24.52 on Wednesday after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance. Macy's, Inc. (NYSE: M) rose 10.83 percent to close at $33.17 after the company reported stronger-than-expected results for its first quarter and lifted guidance. ChemoCentryx, Inc. (NASDAQ: CCXI) gained 9.36 percent to close at $12.50. Canaccord Genuity initiated coverage on ChemoCentryx with a Buy rating. Biolinerx Ltd/S ADR (NASDAQ: BLRX)
• [By Peter Graham]

  Small cap pain stock Pain Therapeutics (NASDAQ: PTIE) has elevated short interest of 35.77% according to Highshortinterest.com. Pain Therapeutics�develops proprietary drugs that offer significant improvements to patients and physicians.�The Company��s�expertise consists of developing new drugs and guiding these through various regulatory and development pathways in preparation for their eventual commercialization with a focus�on drug development efforts around disorders of the nervous system.�The FDA has not yet established the safety or efficacy of�any drug candidates. Pain Therapeutics���pipeline of drug assets includes:

• [By Brian Orelli]

  DURECT Corp. (NASDAQ:DRRX) is down 9.2% at 12:45 p.m. EDT after the U.S. Food and Drug Administration's advisory committee voted�14 to 3 recommending the agency not approve Remoxy ER, an abuse-deterrent extended-release pain medication being developed by its partner Pain Therapeutics�(NASDAQ: PTIE).

Hot Dividend Stocks To Invest In 2019: Elbit Systems Ltd.(ESLT)

Advisors' Opinion:

• [By Stephan Byrd]

  BidaskClub upgraded shares of Elbit Systems (NASDAQ:ESLT) from a sell rating to a hold rating in a report issued on Wednesday.

  Several other equities research analysts have also weighed in on the company. ValuEngine upgraded Elbit Systems from a hold rating to a buy rating in a report on Thursday, March 1st. TheStreet lowered Elbit Systems from a b rating to a c+ rating in a report on Tuesday, May 29th. Finally, Chardan Capital restated a neutral rating on shares of Elbit Systems in a report on Friday, June 1st. Five investment analysts have rated the stock with a hold rating, Elbit Systems presently has an average rating of Hold and an average price target of $176.00.

• [By Logan Wallace]

  Shares of Elbit Systems Ltd (NASDAQ:ESLT) have been given an average rating of “Hold” by the five research firms that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation.

• [By Lisa Levin] Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) rose 7.3 percent to $6.90 in pre-market trading after the company reported the FDA approval of TX-004HR: IMVEXXY (estradiol vaginal inserts) for moderate to severe dyspareunia due to menopause. Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) rose 6.1 percent to $10.50 in pre-market trading after falling 1.20 percent on Tuesday Movado Group, Inc. (NYSE: MOV) shares rose 5.7 percent to $44.60 in pre-market trading after the company reported better-than-expected Q1 results and raised its guidance. salesforce.com, inc. (NYSE: CRM) rose 5.4 percent to $133.67 in pre-market trading after the company reported better-than-expected earnings for its first quarter and raised its forecast for the full year. Sirius XM Holdings Inc. (NASDAQ: SIRI) rose 5.3 percent to $7.35 in pre-market trading. PagSeguro Digital Ltd. (NYSE: PAGS) rose 5.3 percent to $33.50 in pre-market trading after reporting Q1 results. SpartanNash Co (NASDAQ: SPTN) rose 4.9 percent to $19.80 in pre-market trading after the company reported upbeat earnings for its first quarter on Tuesday. Groupon, Inc. (NASDAQ: GRPN) rose 4.9 percent to $4.95 in pre-market trading. Dalian Wanda will set up a joint venture with Tencent and Groupon's former local unit, Reuters reported. Okta, Inc. (NASDAQ: OKTA) rose 4.4 percent to $56 in pre-market trading after gaining 3.43 percent on Tuesday Elbit Systems Ltd. (NASDAQ: ESLT) rose 4.3 percent to $120.92 in pre-market trading after gaining 2.05 percent on Tuesday. STMicroelectronics N.V. (NYSE: STM) shares rose 3.7 percent to $23.78 in pre-market trading after falling 4.70 percent on Tuesday. EVINE Live Inc (NASDAQ: EVLV) shares rose 2.7 percent to $1.14 in pre-market trading after reporting Q1 results.

  Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Hot Dividend Stocks To Invest In 2019: Aurinia Pharmaceuticals Inc(AUPH)

Advisors' Opinion:

• [By Logan Wallace]

  Isotechnika Pharma Inc. (NASDAQ:AUPH) (TSE:AUP) shares rose 6.7% during trading on Friday . The stock traded as high as $5.68 and last traded at $5.59. Approximately 54,590 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 429,596 shares. The stock had previously closed at $5.24.

• [By Keith Speights]

  That statement comes to mind when I think about Aurinia Pharmaceuticals (NASDAQ:AUPH). The potential for the clinical-stage biotech appears to be so great that getting greedy with the stock is tempting.�

• [By Cory Renauer]

  Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH),�a clinical-stage biotech, are on the rise following the company's first-quarter earnings report. Plans to expand voclosporin, the company's lupus candidate, to a much larger indication inspired investors to push the shares 10.2% higher as of 1:03 p.m. Monday.